Your browser doesn't support javascript.
loading
The Complex Structure of the Pharmacological Drug-Disease Network.
López-Rodríguez, Irene; Reyes-Manzano, Cesár F; Guzmán-Vargas, Ariel; Guzmán-Vargas, Lev.
Afiliação
  • López-Rodríguez I; Laboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Av. IPN No. 2580, L. Ticomán, Ciudad de México 07340, Mexico.
  • Reyes-Manzano CF; Tecnológico Nacional de México, Tecnológico de Estudios Superiores de Ixtapaluca, Km. 7 Carretera Ixtapaluca-Coatepec S/N San Juan, Ixtapaluca, Estado de Mexico 56580, Mexico.
  • Guzmán-Vargas A; Laboratorio de Investigación en Materiales Porosos, Instituto Politécnico Nacional-ESIQIE, Catálisis Ambiental y Química Fina, UPALM, Edificio 7 P. B., Zacatenco, C. P., Ciudad de México 07738, Mexico.
  • Guzmán-Vargas L; Laboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Av. IPN No. 2580, L. Ticomán, Ciudad de México 07340, Mexico.
Entropy (Basel) ; 23(9)2021 Aug 31.
Article em En | MEDLINE | ID: mdl-34573762
ABSTRACT
The complexity of drug-disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug-disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures).
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article